AVTX — Avalo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $16.48m
- $9.07m
- $1.92m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -16.1 | -63.5 | -84.4 | -41.7 | -31.5 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -4.94 | 25.4 | 8.97 | 9.94 | 9.93 |
Discontinued Operations | |||||
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2.03 | -4.44 | 2.84 | 4.77 | -9.24 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -19.1 | -40.5 | -70.9 | -26.8 | -30.7 |
Capital Expenditures | -0.262 | -0.063 | -0.113 | -0.095 | -0.158 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.181 | 11.2 | 0 | — | 0.025 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.443 | 11.1 | -0.113 | -0.095 | -0.133 |
Financing Cash Flow Items | 2.79 | 3.79 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 12.6 | 44.8 | 107 | -14.7 | 25 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -7.02 | 15.4 | 35.8 | -41.5 | -5.77 |